Update - Nuvectis Pharma to Participate in a Fireside Chat at the 34th Annual Roth Conference
Nuvectis Pharma announced that CEO Ron Bentsur will participate in a fireside chat at the 34th Annual Roth Conference on March 15, 2022, at 2:30 PM PT (5:30 PM ET).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nuvectis Pharma announced that CEO Ron Bentsur will participate in a fireside chat at the 34th Annual Roth Conference on March 15, 2022, at 2:30 PM PT (5:30 PM ET). The conference will showcase the company's focus on innovative precision medicines for oncology. Nuvectis is developing NXP800, a clinical-stage HSF1-pathway inhibitor, and NXP900, a SRC/YES1 kinase inhibitor currently in IND-enabling pre-clinical testing. More details can be found on their website.
Details
News Market Reaction – NVCT
The recorded move for NVCT in the trading session of this news was +4.60%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 34th Annual Roth Conference.
| Event | 34th Annual Roth Conference |
| Date | March 15, 2022 |
| Time | 2:30 PM Pacific Time (5:30 PM Eastern Time) |
| Format | Fireside Chat |
| Link | https://wsw.com/webcast/roth43/nvct/1845484 |
About Nuvectis Pharma
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. The Company's pipeline includes NXP800, a clinical-stage HSF1-pathway inhibitor, and NXP900, a SRC/YES1 kinase inhibitor in IND-enabling pre-clinical testing.
For more information, please visit www.nuvectis.com.
Nuvectis Pharma Contact:
Ron Bentsur
Chairman, Chief Executive Officer and President
Media Relations Contact:
LifeSci Advisors on behalf of Nuvectis Pharma, Inc.
Eric Goldstein
Tel: 646-791-9729
egoldstein@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.